Wednesday, July 8, 2026

biotech · Breast Cancer · Sarcoma,Soft Tissue · INTS

INTENSITY THERAPEUTICS

Intensity Therapeutics is a biotech organization headquartered in Shelton, USA. It trades on NYSE under ticker INTS. Primary therapeutic focus areas include Breast Cancer, Sarcoma,Soft Tissue, EGFR Mutant Advanced Non-sm

Shelton, USA HQ
2012 Founded
12 Employees
Public company Type
INTS · NYSE Ticker
Company details
Status
Public
HQ
Shelton, USA
Founded
2012
Employees
12
Programs
6
Drugs
9
Patents
3
Clinical program

MPT0B640

Phase 1 · small molecule · Covid19

MPT0B640 for Covid19 is a Phase 1 program (small_molecule) at INTENSITY THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All INTENSITY THERAPEUTICS, INC. projects Phase 1 small molecule terminated

Internal code JO201901-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
INTENSITY THERAPEUTICS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Covid19
Status
terminated
Trials
1

Clinical trials